HIV Scientific Papers
Long-acting ibalizumab in patients with multi-drug resistant HIV-1: a 24-week study [abstract].
2017
Top Antivir Med.
Lewis S, Fessel J, Emu B, et al.
"27(suppl 1):185s. Proceedings of the 2018 Conference on Retroviruses and Opportunistic Infections. "
Long-acting ibalizumab in patients with multi-drug resistant HIV-1: a 24-week study.
2017
Lewis S, Fessel J, Emu B, et al.
Poster #449LB presented at: Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington, USA.
Intramuscular ibalizumab: pharmacokinetics, safety, and efficacy vs IV administration [abstract].
2017
Lin H-H, Lee SS-J, Wang N-C, et al.
"27(suppl 1):180s. Proceedings of the 2018 Conference on Retroviruses and Opportunistic Infections. "
Intramuscular ibalizumab: pharmacokinetics, safety, and efficacy vs IV administration.
2017
Lin H-H, Lee SS-J, Wang N-C, et al.
Poster #2181 presented at: Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington, USA.
Forty-eight-week safety and efficacy on-treatment analysis of ibalizumab in patients with multi-drug resistant HIV-1 [abstract].
2017
Open Forum Infect Dis.
Emu B, Fessel J, Schrader S, et al.
4(suppl 1):S38-S39. Proceedings of IDWeek, 2017.